Tag Archive for ‘DCIS’

Trials explore whether endocrine therapy can delay or avert surgery in low-risk DCIS

Over the last several decades, the widespread implementation and uptake of screening mammography has contributed to earlier diagnosis of breast cancer and improvements in breast cancer mortality. However, the screening has led to a significant rise in the detection of ductal carcinoma in situ (DCIS), which is a pre-cancer of the breast. Much like invasive […]

FIGURE 1. COMET Trial Schema

Surgery versus monitoring and endocrine therapy for low-risk DCIS: The COMET Trial

The COMET Trial—a prospective randomized study aimed at assessing the risks and benefits associated with active surveillance versus guideline concordant care for patients with low-risk ductal carcinoma in situ—is the focus of this month’s column.

CALGB 40903: Phase II single-arm study of neoadjuvant letrozole for ER(+) postmenopausal DCIS

Reframing treatment for ductal carcinoma in situ: Could less be more?

In a typical breast surgery practice, nearly one-fifth of new patients present with ductal carcinoma in situ (DCIS), usually detected on mammography as an incidental finding. Most of these women are otherwise healthy, take care of themselves, have had a mammogram as part of their routine health maintenance, and are now grappling with a “cancer” […]


Bulletin of the American College of Surgeons
633 N. Saint Clair St.
Chicago, IL 60611


Download the Bulletin App

Apple Store
Get it on Google Play
Amazon store